Opaque conflicts of interest permeate prescription drug benefits; federal panel dismisses calls for broader suicide screening

A largely hidden flow of money between consulting firms and PBMs compromises the firms' ability to choose drug benefits for employers.

June 20, 2023 Check out STAT+

Sponsored By

Eros Dervishi for STAT STAT+ | 'It's beyond unethical': Opaque conflicts of interest permeate prescription drug benefits A largely hidden flow of money between major consulting firms and PBMs compromises the firms' ability to choose drug benefits for employers. By Bob Herman STAT+ | Novo Nordisk sues spas and clinics for selling versions of Wegovy and Ozempic for weight loss Novo Nordisk accused the spas and clinics of false advertising, unfair competition and infringing on trademarks for Ozempic and Wegovy. By Ed Silverman Government panel dismisses calls for broader suicide risk screening A panel of government advisers is sticking with its recommendation that providers screen most adults for major depression. By Sarah Owermohle Alex Hogan/STAT STAT+ | The FDA is testing new nutrition labels on the front of food packages The FDA wants to make it easier for consumers to know if the foods they're buying are unhealthy — but doing so is harder than it seems. By Nicholas Florko STAT+ | How drug pricing reforms are affecting Bayer's investments Despite Democrats' drug pricing reforms, one major pharmaceutical company is doubling down in the U.S. market. By Rachel Cohrs Opinion: Bloated patient records are filled with false information, thanks to copy-paste Today's chart notes, filled with unnecessary and often copied details, are causing physicians to make diagnostic errors. By Sandeep Jauhar Darron Cummings/AP STAT+ | Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal DICE's lead program is an oral drug that aims to inhibit a signaling chemical involved in a cascade of reactions that leads to inflammation. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser